How BPC-157 works: a plain-English guide

BPC-157 is a 15-amino-acid synthetic peptide originally isolated from a protein in human gastric juice (the digestive fluid your stomach produces)^[1]. In rodent and cell-culture studies, it appears to accelerate tissue repair through a handful of interconnected signalling pathways. Here is what the preclinical literature actually describes, with every technical term glossed in plain English.

The short version

Three mechanisms come up repeatedly in the animal data: angiogenesis (the growth of new blood vessels into damaged tissue), nitric-oxide signalling (the system that controls how blood vessels widen and contract), and growth-factor pathway modulation (the chemical signals that tell cells when to grow, divide, and repair). None of these has been confirmed in a human clinical trial^[2].

Angiogenesis and VEGF

The most-cited proposed mechanism is angiogenesis. In rat injury models, BPC-157 administration is associated with increased expression of VEGFR2 (vascular endothelial growth factor receptor 2, the protein on blood-vessel cells that receives the 'grow new vessels' signal). When VEGFR2 activity rises, more capillaries form in the damaged area, and that improved blood supply supports tissue repair^[3].

A 2011 study by Chang and colleagues tested BPC-157 on rat tendon explants and cultured tendon fibroblasts. They found that the peptide significantly accelerated the outgrowth of tendon tissue from the explant, increased cell survival under oxidative stress (a condition that mimics the hostile environment inside an injury), and increased tendon-fibroblast migration (the movement of the cells that build tendon tissue toward the injury site) in a dose-dependent manner^[4]. The signalling pathway involved was FAK-paxillin (focal adhesion kinase and its binding partner, both of which regulate how cells attach to surfaces and move through tissue).

Nitric-oxide signalling

A 2020 paper by Hsieh and colleagues in Scientific Reports tested BPC-157 on isolated rat aortic tissue and on cultured endothelial cells (the cells that line blood vessels). The peptide produced concentration-dependent vasodilation (relaxation of the vessel wall), and that effect was endothelium-dependent: when the researchers removed the endothelial layer, the relaxation largely disappeared^[3].

The pathway they identified runs through three proteins: Src (a signalling enzyme), Caveolin-1 (a structural protein in the cell membrane), and eNOS (endothelial nitric oxide synthase, the enzyme that produces nitric oxide in blood-vessel cells). BPC-157 triggered Src activation, which loosened the binding between Caveolin-1 and eNOS, freeing eNOS to produce more nitric oxide. When the researchers blocked Src with an inhibitor, the effect on eNOS phosphorylation dropped substantially^[3].

Growth-factor pathways and the gut-brain axis

Beyond VEGF, rodent studies report that BPC-157 modulates other growth factors, including basic FGF (fibroblast growth factor, a protein involved in wound healing and new-tissue formation). The Zagreb group, led by Predrag Sikiric, has also published work suggesting BPC-157 influences the gut-brain axis (the two-way nerve-and-hormone communication between the digestive system and the central nervous system). These findings are summarised in a 2024 review in Inflammopharmacology covering more than 130 references accumulated over three decades of work^[1].

The gut-brain axis work is the least replicated of the three proposed pathways. The claim is that BPC-157 modulates dopamine and serotonin system activity in rodent models of brain injury and substance-withdrawal, but the experiments are small, the endpoints vary between papers, and no independent group has published a confirmatory study. The mechanistic picture is plausible on paper, but it remains entirely preclinical.

What this is not

This is not a confirmed human mechanism. There is no published phase-2 or phase-3 trial of BPC-157 for any indication. The US Department of Defense's Operation Supplement Safety programme describes BPC-157 as 'an unapproved drug' with 'little to no reliable scientific evidence to support the safety or effectiveness of BPC-157 in humans'^[5]. USADA echoes that assessment, noting that 'no one knows if there is a safe dose, or if there is any way to use this compound safely'^[6].

Most of the published work comes from a small number of research groups, with the Zagreb laboratory producing the largest share. A 2026 STAT News investigation noted that the 'amount of hype to evidence is just so skewed' and that the two PLIVA-era clinical trials from the 2000s testing BPC-157 enemas for ulcerative colitis were never published in peer-reviewed journals^[2]. That concentration is not unusual in early-stage peptide research, but it means the findings have had limited independent replication.

Where this sits on the site

The full BPC-157 peptide page covers regulatory status, supply-chain quality signals, the WADA prohibition, and the practical picture. The regulation pages break down the country-by-country legal position. This article covers only the proposed mechanism. If you are considering BPC-157, that conversation belongs with a clinician who knows your medical history.